Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide + cetuximab with platinum-based chemotherapy in first-line advanced NSCLC
2008-004148-35Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2008
- Modality
- Modified Peptides → Peptides, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of cilengitide and cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Maximum tolerated dose of cilengitide (safety run-in) and Progression-free survival. Started Aug 2008; status: completed.
02
Drugs
cilengitidecetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004148-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004148-35.